We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urinary Tract Biopsy Correlates Urothelial Carcinoma Diagnosis

By LabMedica International staff writers
Posted on 28 Sep 2017
Urothelial carcinoma (UCC), also known as transitional cell carcinoma (TCC) is a type of cancer that typically occurs in the urinary system. More...
It is the most common type of bladder cancer and cancer of the ureter.

UCC is the second most common type of kidney cancer, but accounts for only five to 10% of all primary renal malignant tumors. UCC arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. Transitional cell carcinoma (TCC) accounts for more than 95% of urothelial tumors of the upper urinary tract.

Scientists at the University of Chicago (Chicago, IL, USA) searched their Department of Pathology archive for all cases of upper urothelial tract biopsies and washings between the years 2005 and 2015 that had nephroureterectomy for urothelial carcinoma. In all, 126 patients met the inclusion criteria. They considered cytology diagnoses of either urothelial cancer or “suspicious for urothelial cancer” to be positive. They compared the concordance between combined biopsy and washing, and then compared biopsy and washing diagnoses with the presence of carcinoma on resection.

The team found that from the 126 patients who had resection, only 72 patients had prior diagnostic material. Of those, 33 (26%) had combined biopsy and washing, 26 (21%) had biopsy only, and 13 (10%) had washing only. Among the patients who had had both procedures, 15 (45%) of the diagnoses were concordant as indicated by positive biopsy and cytology, and the final resection specimen revealed urothelial carcinoma. One patient, who was considered concordant, had negative results for both procedures but had urothelial carcinoma on resection.

The scientists found that among the 17 discordant combined biopsy and cytology cases, 11 had positive biopsy with negative washing, four had negative biopsy with positive washing and for two cases, neither biopsy nor washing was diagnostic. Among the 11 positive biopsies with negative washing, five were low-grade papillary urothelial cancer, four were high-grade papillary urothelial cancer, one was urothelial cancer in situ, and one was high-grade urothelial cancer suspicious for invasion.

Providers often obtain biopsies and cytology washings of the upper urinary tract to help them diagnose urothelial cancer, but may have only one procedure performed. Shiraz Fidai, MD, and Tatjana Antic, MD, co-authors of the study, said, “Overall, based on our data, both biopsies and washings of the upper tract (83% for biopsies and 59% for washings) are appropriate in diagnosing urothelial cancer. However, biopsies are more suitable for diagnosing low-grade papillary urothelial cancer when compared with cytology. Size and multifocality of the urothelial cancer of the upper urinary tract plays a significant role in obtaining an adequate specimen for either diagnosis or grading.” The study was presented at the Annual Meeting of the American Society for Clinical Pathology (ASCP), held September 6-8, 2017, in Chicago, IL, USA.

Related Links:
University of Chicago


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.